<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655823</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-CINP-201</org_study_id>
    <nct_id>NCT01655823</nct_id>
  </id_info>
  <brief_title>The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment</brief_title>
  <acronym>TTX-CINP-201</acronym>
  <official_title>A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wex Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wex Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of
      many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin,
      bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in
      greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing
      is often either decreased or discontinued potentially affecting tumor responsiveness,
      prognosis, and survival.

      There is an unmet medical need for treatment of cancer patients with chemotherapy induced
      neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of
      multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic
      pain caused by chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis completed and decided to terminate and proceed to Phase 3 trial.
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 11, 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.</measure>
    <time_frame>Day 22 to Day 28</time_frame>
    <description>The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Pain</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Placebo (twice daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for injection (1 ml volume), twice a day for four consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Tetrodotoxin (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-range dose of Tetrodotoxin (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Max dose Tetrodotoxin (once daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Max dose Tetrodotoxin (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sham treatment acting as control arm</description>
    <arm_group_label>Max dose Tetrodotoxin (once daily)</arm_group_label>
    <arm_group_label>Placebo (twice daily)</arm_group_label>
    <other_name>placebo for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrodotoxin</intervention_name>
    <description>Comparison of different dosages of Tetrodotoxin</description>
    <arm_group_label>Low dose Tetrodotoxin (twice daily)</arm_group_label>
    <arm_group_label>Max dose Tetrodotoxin (once daily)</arm_group_label>
    <arm_group_label>Max dose Tetrodotoxin (twice daily)</arm_group_label>
    <arm_group_label>Mid-range dose of Tetrodotoxin (twice daily)</arm_group_label>
    <other_name>TTX for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, not of childbearing potential.

          -  Patients with documented neuropathic pain

          -  Cancer Patients who have completed a chemotherapy regimen which included taxanes or
             platinums (or both) and have no evidence actively progressive disease. Concurrent
             hormonal therapies are allowed

          -  Patients with stable moderate to severe neuropathic pain

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status score of
             0 or 1.

          -  Patients who are able to complete the study-related questionnaires independently in
             either English or Spanish.

        Exclusion Criteria:

          -  History of peripheral neuropathy attributed to any cause other than chemotherapy.

          -  Patients receiving any concurrent agents known to cause peripheral neuropathy within
             30 days of Randomization.

          -  Current use of other therapy (ies), including &quot;alternative&quot; therapies, for treatment
             of peripheral neuropathy within 30 days of Randomization (with the exception of
             protocol allowed concurrent medications).

          -  Patients who used controlled release opioids within seven days of baseline period or
             who expect to use controlled release opioids at any time from baseline to end of
             study.

          -  Patients with abnormal kidney function.

          -  Patients with bone metastases.

          -  Patients scheduled for treatment for their cancer with chemotherapy or radiotherapy
             between screening and the end of study visit.

          -  Current use of lidocaine and other types of antiarrhythmic drugs within 30 days of
             Randomization.

          -  Current use of scopolamine and acetylcholinesterase-inhibiting drugs such as
             physostigmine within 30 days of Randomization.

          -  Current cause of Chemotherapy Induced Neuropathic Pain attributed to Velcade
             (Bortezomib) or vinca alkaloids or analogues such as vincristine, vinblasine,
             vinorelbine and vindesine.

          -  Current use of tricyclic antidepressant medication, anticonvulsants and monoamine
             oxidase inhibitors.

          -  Patients with current uncontrolled asthma or lung disease.

          -  Patients with significant heart disease.

          -  Use of an investigational agent within 30 days prior to screening or is scheduled to
             receive an investigational drug other than TTX during the course of the study.

          -  Females who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Goldlust, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lalita Pandit</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Moss</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Centers</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Research Management</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Cancer Center</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medsol Clinical Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axcess Medical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Middle Georgia</name>
      <address>
        <city>Dublin</city>
        <state>Georgia</state>
        <zip>31021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pain Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <results_first_submitted>August 16, 2018</results_first_submitted>
  <results_first_submitted_qc>October 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Puffer fish</keyword>
  <keyword>Tetrodotoxin</keyword>
  <keyword>TTX</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>WEX Pharmaceuticals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrodotoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Twice Daily)</title>
          <description>Placebo for injection (1 ml volume), twice a day for four consecutive days.
Placebo: Sham treatment acting as control arm</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Tetrodotoxin (Twice Daily)</title>
          <description>Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="P3">
          <title>Mid-range Dose of Tetrodotoxin (Twice Daily)</title>
          <description>Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="P4">
          <title>Max Dose Tetrodotoxin (Once Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Placebo: Sham treatment acting as control arm
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="P5">
          <title>Max Dose Tetrodotoxin (Twice Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Twice Daily)</title>
          <description>Placebo for injection (1 ml volume), twice a day for four consecutive days.
Placebo: Sham treatment acting as control arm</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Tetrodotoxin (Twice Daily)</title>
          <description>Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="B3">
          <title>Mid-range Dose of Tetrodotoxin (Twice Daily)</title>
          <description>Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="B4">
          <title>Max Dose Tetrodotoxin (Once Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Placebo: Sham treatment acting as control arm
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="B5">
          <title>Max Dose Tetrodotoxin (Twice Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="10.3"/>
                    <measurement group_id="B2" value="59.1" spread="10.29"/>
                    <measurement group_id="B3" value="61.4" spread="10.01"/>
                    <measurement group_id="B4" value="60.4" spread="10.28"/>
                    <measurement group_id="B5" value="60.6" spread="11.05"/>
                    <measurement group_id="B6" value="60.1" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.</title>
        <description>The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).</description>
        <time_frame>Day 22 to Day 28</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Twice Daily)</title>
            <description>Placebo for injection (1 ml volume), twice a day for four consecutive days.
Placebo: Sham treatment acting as control arm</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Tetrodotoxin (Twice Daily)</title>
            <description>Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
          </group>
          <group group_id="O3">
            <title>Mid-range Dose of Tetrodotoxin (Twice Daily)</title>
            <description>Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
          </group>
          <group group_id="O4">
            <title>Max Dose Tetrodotoxin (Once Daily)</title>
            <description>Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Placebo: Sham treatment acting as control arm
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
          </group>
          <group group_id="O5">
            <title>Max Dose Tetrodotoxin (Twice Daily)</title>
            <description>Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.</title>
          <description>The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).</description>
          <population>ITT</population>
          <units>11 point units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.662" spread="1.4832"/>
                    <measurement group_id="O2" value="6.285" spread="1.3312"/>
                    <measurement group_id="O3" value="7.012" spread="1.3706"/>
                    <measurement group_id="O4" value="6.240" spread="1.1743"/>
                    <measurement group_id="O5" value="6.255" spread="1.3561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Scores for Days 22-28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.323" spread="2.2765"/>
                    <measurement group_id="O2" value="5.005" spread="2.0451"/>
                    <measurement group_id="O3" value="5.987" spread="2.2531"/>
                    <measurement group_id="O4" value="4.566" spread="2.4931"/>
                    <measurement group_id="O5" value="4.749" spread="1.7701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Mean Scores for Days 22-28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.339" spread="2.0681"/>
                    <measurement group_id="O2" value="-1.269" spread="1.3959"/>
                    <measurement group_id="O3" value="-1.052" spread="1.5742"/>
                    <measurement group_id="O4" value="-1.682" spread="2.3231"/>
                    <measurement group_id="O5" value="-1.529" spread="1.8203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Twice Daily)</title>
          <description>Placebo for injection (1 ml volume), twice a day for four consecutive days.
Placebo: Sham treatment acting as control arm</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Tetrodotoxin (Twice Daily)</title>
          <description>Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="E3">
          <title>Mid-range Dose of Tetrodotoxin (Twice Daily)</title>
          <description>Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="E4">
          <title>Max Dose Tetrodotoxin (Once Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Placebo: Sham treatment acting as control arm
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
        <group group_id="E5">
          <title>Max Dose Tetrodotoxin (Twice Daily)</title>
          <description>Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Tetrodotoxin: Comparison of different dosages of Tetrodotoxin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic carcinoma of bladder and Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mehran Kavoosi</name_or_title>
      <organization>Wex Pharmaceuticals</organization>
      <phone>6046767900</phone>
      <email>mehrank@wexpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

